Stuttgart - Delayed Quote EUR

KES/USD (AXD2.SG)

1.8770

-0.1200

(-6.01%)

At close: May 6 at 8:00:48 AM GMT+2

Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks 13 hours ago

HRTX
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 200% and 4.93%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 13 hours ago

HRTX

STVN
Heron Therapeutics: Q1 Earnings Snapshot

CARY, N.C. (AP) — Heron Therapeutics Inc. HRTX) on Tuesday reported net income of $2.6 million in its first quarter. The Cary, North Carolina-based company said it had net income of 1 cent per share.

Associated Press Finance 14 hours ago

HRTX
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates.

PR Newswire 15 hours ago

HRTX
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related to CINVANTI® (aprepitant) injectable emulsion and APONVIE® (aprepitant) injectable emulsion. Pursuant to the terms of the settl

PR Newswire 15 hours ago

HRTX
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 5 days ago

AKBA

HRTX
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 7 days ago

HRTX
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry.

PR Newswire 8 days ago

HRTX
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics are part of the Zacks Industry Outlook article.

Zacks 12 days ago

AUPH

HRTX

ESPR
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

Zacks 13 days ago

PSTV

HRTX

AUPH
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks 13 days ago

EXAS

HRTX
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, May 6, 2025, at 8:00 a.m. ET to report first quarter 2025 financial results and discuss recent business highlights.

PR Newswire 14 days ago

HRTX
Best Momentum Stocks to Buy for April 22nd

DPMLF, HRTX and FOX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 22, 2025.

Zacks 14 days ago

HRTX

FOXA
Are Medical Stocks Lagging Encompass Health (EHC) This Year?

Here is how Encompass Health (EHC) and Heron Therapeutics (HRTX) have performed compared to their sector so far this year.

Zacks 14 days ago

EHC

HRTX
Exploring High Growth Tech Stocks In The US Market April 2025

Over the last 7 days, the United States market has dropped 5.6%, yet it has risen by 3.3% over the past year, with earnings expected to grow by 14% per annum in the coming years. In this fluctuating environment, identifying high growth tech stocks requires a focus on companies that demonstrate robust innovation and adaptability to capitalize on future opportunities.

Simply Wall St. last month

CAN

GAMB

HRTX
Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected To Breakeven In The Medium-Term

Heron Therapeutics, Inc. ( NASDAQ:HRTX ) is possibly approaching a major achievement in its business, so we would like...

Simply Wall St. last month

HRTX
Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5?

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Heron Therapeutics, Inc. (NASDAQ:HRTX) stands against other hot biotech stocks under $5. The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. After a […]

Insider Monkey last month

HRTX
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported Earnings, And Analysts Cut Their Target Price

As you might know, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) just kicked off its latest annual results with some very...

Simply Wall St. 2 months ago

HRTX
High Growth Tech Stocks to Watch in US Market February 2025

Over the last 7 days, the United States market has dropped 4.8%, yet it remains up by 15% over the past year with earnings forecast to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that can capitalize on technological advancements and maintain robust growth trajectories despite short-term market fluctuations.

Simply Wall St. 2 months ago

BIGC

HRTX

INCY
Heron Therapeutics (NASDAQ:HRTX) shareholders are up 19% this past week, but still in the red over the last five years

It is doubtless a positive to see that the Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price has gained some 72% in...

Simply Wall St. 2 months ago

HRTX

Performance Overview

Return	AXD2.SG	S&P 500 (^GSPC)
YTD	+28.56%	-4.67%
1-Year	-27.14%	+8.23%
3-Year	-50.16%	+35.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

KES/USD (AXD2.SG)

Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics

Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates

Heron Therapeutics: Q1 Earnings Snapshot

Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

Best Momentum Stocks to Buy for April 22nd

Are Medical Stocks Lagging Encompass Health (EHC) This Year?

Exploring High Growth Tech Stocks In The US Market April 2025

Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected To Breakeven In The Medium-Term

Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5?

Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported Earnings, And Analysts Cut Their Target Price

High Growth Tech Stocks to Watch in US Market February 2025

Heron Therapeutics (NASDAQ:HRTX) shareholders are up 19% this past week, but still in the red over the last five years

Performance Overview